Clinical Trial Update: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]

View source ↗

Summary

A Phase 3 trial of fedratinib in patients with primary myelofibrosis and myelofibrosis after polycythemia vera or essential thrombocythemia was terminated, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• fedratinib (fedratinib)

Snippet

Sponsor: Celgene | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Status: TERMINATED | Results posted: 2023-03-09